The U.S. Hemp Roundtable sent a letter Friday to Senators Chuck Schumer, Ron Wyden and Cory Booker, who are the leading sponsors of a recently presented, but long-awaited comprehensive cannabis legalization bill - Cannabis Administration Opportunity Act (CAOA). While the non-profit advocacy organization praised the bill’s introduction it has also suggested several changes to provisions within the measure that could negatively affect the hemp industry.
The Roundtable’s general counsel, Jonathan Miller offered two crucial suggestions:
1. Re-Defining Hemp
The language in the bill states that the permissible amount of THC for products made or derived from hemp can’t exceed 1 milligram of total THC per 100 grams on a dry weight basis, or in other words, created 0.001% total THC standard. Which is “an arbitrary and unrealistic” standard, according to the organization.
Under the bill, most broad-spectrum hemp extracts wouldn’t qualify in addition to CBD isolates having trouble complying. “Indeed, this limit would delegate most, if not all, popular, non-intoxicating CBD and hemp extract products to the adult-use cannabis market,” Miller stated.
The proposed THC limit would knock a booming industry, and additionally, limit possibilities for hemp farms that are already dealing with a lot of challenges. Miller further highlighted that the organization is not familiar with any scientific data that confirms that 1mg THC/100g is an appropriate limit for hemp products.
2. Regulating CBD
The proposed regulations to include the sale of hemp-derived CBD as a dietary supplement are “unequally onerous.”
The organization proposed the following changes: broadening protections to all non-intoxicating hemp derivatives and cannabinoids, instead of CBD only; enabling companies to use all standard methods of safety evaluations allowed by law, rather than requiring a new dietary ingredient notification (NDINs); and, creating an extra pathway for the sale of hemp extract like CBD as food and beverage ingredients.
Most of the things in the new letter are repeating the same comments the U.S. Hemp Roundtable made to the bill’s draft last year.
Photo Benzinga Edit: Peter Pike by Pixabay and Wikimedia Commons
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.